Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)320-321
Number of pages2
JournalBritish Journal of Dermatology
Issue number2
Early online date14 Feb 2018
Publication statusPublished - Feb 2018


  • Cost-Benefit Analysis
  • Doxycycline
  • Humans
  • Pemphigoid, Bullous
  • Prednisolone
  • Quality-Adjusted Life Years

Cite this